Natixis Legend Biotech Corp Transaction History
Natixis
- $17.4 Billion
- Q2 2024
A detailed history of Natixis transactions in Legend Biotech Corp stock. As of the latest transaction made, Natixis holds 1,065 shares of LEGN stock, worth $51,684. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,065
Previous 1,404
24.15%
Holding current value
$51,684
Previous $78,000
39.74%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding LEGN
# of Institutions
198Shares Held
74.2MCall Options Held
374KPut Options Held
387K-
Price T Rowe Associates Inc Baltimore, MD11.5MShares$558 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.51MShares$364 Million5.01% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.64MShares$322 Million7.6% of portfolio
-
Black Rock Inc. New York, NY5.72MShares$278 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.77MShares$232 Million1.06% of portfolio
About Legend Biotech Corp
- Ticker LEGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 167,403,008
- Market Cap $8.12B
- Description
- Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...